Advertisement
Screener

Opus Genetics, Inc. (IRD) License Costs (Deprecated 2018-01-31)

2.8 / 5 stars · 68/120 Roast Me

Opus Genetics, Inc. License Costs (Deprecated 2018-01-31)

Opus Genetics, Inc. (IRD) reported License Costs (Deprecated 2018-01-31) of $101.38 thousand for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-12.

Discontinued › Expense Statement › Operating Expenses

us-gaap:LicenseCosts · last filed 2018-05-04

  • Opus Genetics, Inc. license costs (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $101.38K, a 1.18% increase year-over-year.
  • Opus Genetics, Inc. license costs (deprecated 2018-01-31) for the quarter ending 2014-06-30 was $95.41K, a 21.29% decline year-over-year.
  • Opus Genetics, Inc. license costs (deprecated 2018-01-31) for the quarter ending 2014-03-31 was $72.02K, a 47.23% decline year-over-year.
  • Opus Genetics, Inc. license costs (deprecated 2018-01-31) for the quarter ending 2013-12-31 was $70.30K, a 45.32% decline year-over-year.
  • Opus Genetics, Inc. license costs (deprecated 2018-01-31) for fiscal 2013 was $428.20K, a 0.67% decline from fiscal 2012.
  • Opus Genetics, Inc. license costs (deprecated 2018-01-31) for fiscal 2012 was $431.10K, a 21.05% decline from fiscal 2011.
  • Opus Genetics, Inc. license costs (deprecated 2018-01-31) for fiscal 2011 was $546.03K, a 65.50% increase from fiscal 2010.
  • Opus Genetics, Inc. license costs (deprecated 2018-01-31) for fiscal 2010 was $329.93K.
Period endLicense Costs (Deprecated 2018-01-31) 3 monthLicense Costs (Deprecated 2018-01-31) 6 monthLicense Costs (Deprecated 2018-01-31) 9 monthLicense Costs (Deprecated 2018-01-31) 12 monthLicense Costs (Deprecated 2018-01-31) 12 month as first filedLicense Costs (Deprecated 2018-01-31) 132 monthLicense Costs (Deprecated 2018-01-31) 135 monthLicense Costs (Deprecated 2018-01-31) 138 monthLicense Costs (Deprecated 2018-01-31) 141 monthLicense Costs (Deprecated 2018-01-31) 144 monthLicense Costs (Deprecated 2018-01-31) 147 monthLicense Costs (Deprecated 2018-01-31) 150 monthLicense Costs (Deprecated 2018-01-31) 153 monthLicense Costs (Deprecated 2018-01-31) 156 month
2014-09-30$101.38K
10-Q · filed 2014-11-12
$196.79K
derived: sum of 2 quarters · filed 2014-11-12
$268.81K
10-Q · filed 2014-11-12
$339.11K
derived: sum of 4 quarters · filed 2014-11-12
2014-06-30$95.41K
10-Q · filed 2014-08-13
$167.43K
10-Q · filed 2014-08-13
$237.73K
derived: sum of 3 quarters · filed 2014-08-13
$337.93K
derived: sum of 4 quarters · filed 2014-11-12
2014-03-31$72.02K
10-Q · filed 2014-05-14
$142.32K
derived: sum of 2 quarters · filed 2014-05-14
$242.52K
derived: sum of 3 quarters · filed 2014-11-12
$363.73K
derived: sum of 4 quarters · filed 2014-11-12
$3.03M
10-Q · filed 2014-05-14
2013-12-31$70.30K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21
$170.50K
derived: sum of 2 quarters · filed 2014-11-12
$291.71K
derived: sum of 3 quarters · filed 2014-11-12
$428.20K
10-K · filed 2014-03-21
$2.96M
10-K · filed 2014-03-21
2013-09-30$100.20K
10-Q · filed 2014-11-12
$221.41K
derived: sum of 2 quarters · filed 2014-11-12
$357.91K
10-Q · filed 2014-11-12
$486.47K
derived: sum of 4 quarters · filed 2014-11-12
$2.89M
10-Q · filed 2013-11-13
2013-06-30$121.22K
10-Q · filed 2014-08-13
$257.71K
10-Q · filed 2014-08-13
$386.27K
derived: sum of 3 quarters · filed 2014-08-13
$508.84K
derived: sum of 4 quarters · filed 2014-08-13
$2.79M
10-Q · filed 2013-08-12
2013-03-31$136.49K
10-Q · filed 2014-05-14
$265.06K
derived: sum of 2 quarters · filed 2014-05-14
$387.63K
derived: sum of 3 quarters · filed 2014-05-14
$465.00K
derived: sum of 4 quarters · filed 2014-05-14
$2.67M
10-Q · filed 2013-05-09
2012-12-31$128.57K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21
$251.14K
derived: sum of 2 quarters · filed 2014-03-21
$328.51K
derived: sum of 3 quarters · filed 2014-03-21
$431.10K
10-K · filed 2014-03-21
$2.53M
10-K · filed 2013-03-22
2012-09-30$122.57K
10-Q · filed 2013-11-13
$199.94K
derived: sum of 2 quarters · filed 2013-11-13
$302.53K
10-Q · filed 2013-11-13
$474.40K
derived: sum of 4 quarters · filed 2013-11-13
$2.40M
10-Q · filed 2012-11-08
2012-06-30$77.37K
10-Q · filed 2013-08-12
$179.96K
10-Q · filed 2013-08-12
$351.83K
derived: sum of 3 quarters · filed 2013-08-12
$550.25K
derived: sum of 4 quarters · filed 2013-08-12
$2.28M
10-Q · filed 2012-08-08
2012-03-31$102.59K
10-Q · filed 2013-05-09
$274.45K
derived: sum of 2 quarters · filed 2013-05-09
$472.88K
derived: sum of 3 quarters · filed 2013-05-09
$576.10K
derived: sum of 4 quarters · filed 2013-05-09
$2.20M
10-Q · filed 2012-05-09
2011-12-31$171.86K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22
$370.29K
derived: sum of 2 quarters · filed 2013-03-22
$473.51K
derived: sum of 3 quarters · filed 2013-03-22
$546.03K
10-K · filed 2013-03-22
2011-09-30$198.42K
10-Q · filed 2012-11-08
$301.65K
derived: sum of 2 quarters · filed 2012-11-08
$374.16K
10-Q · filed 2012-11-08
$466.00K
derived: sum of 4 quarters · filed 2012-11-08
2011-06-30$103.22K
10-Q · filed 2012-08-08
$175.74K
10-Q · filed 2012-08-08
$267.57K
derived: sum of 3 quarters · filed 2012-08-08
$390.72K
derived: sum of 4 quarters · filed 2012-08-08
2011-03-31$72.51K
10-Q · filed 2012-05-09
$164.35K
derived: sum of 2 quarters · filed 2012-05-09
$287.50K
derived: sum of 3 quarters · filed 2012-05-09
$349.70K
derived: sum of 4 quarters · filed 2012-05-09
2010-12-31$91.84K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-16
$214.98K
derived: sum of 2 quarters · filed 2012-03-16
$277.19K
derived: sum of 3 quarters · filed 2012-03-16
$329.93K
10-K · filed 2012-03-16
2010-09-30$123.15K
10-Q · filed 2011-11-09
$185.35K
derived: sum of 2 quarters · filed 2011-11-09
$238.09K
10-Q · filed 2011-11-09
2010-06-30$62.21K
10-Q · filed 2011-08-09
$114.94K
10-Q · filed 2011-08-09
2009-12-31$100.00K
10-Q · filed 2018-05-04
$303.22K
10-K · filed 2012-03-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Rezolute, Inc. (RZLT)United States$0.382B-6.45
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63